GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Total Liabilities

SSY Group (HKSE:02005) Total Liabilities : HK$4,698 Mil (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group Total Liabilities?

SSY Group's Total Liabilities for the quarter that ended in Dec. 2023 was HK$4,698 Mil.

SSY Group's quarterly Total Liabilities increased from Dec. 2022 (HK$4,420.69 Mil) to Jun. 2023 (HK$4,650.41 Mil) and increased from Jun. 2023 (HK$4,650.41 Mil) to Dec. 2023 (HK$4,697.64 Mil).

SSY Group's annual Total Liabilities increased from Dec. 2021 (HK$4,216.01 Mil) to Dec. 2022 (HK$4,420.69 Mil) and increased from Dec. 2022 (HK$4,420.69 Mil) to Dec. 2023 (HK$4,697.64 Mil).


SSY Group Total Liabilities Historical Data

The historical data trend for SSY Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Total Liabilities Chart

SSY Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,537.19 3,338.50 4,216.01 4,420.69 4,697.64

SSY Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,216.01 4,451.84 4,420.69 4,650.41 4,697.64

SSY Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SSY Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2521.44+(1951.327+224.877
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=4,698

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=11966.336-7268.692
=4,698

SSY Group's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2521.44+(1951.327+224.877
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=4,698

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=11966.336-7268.692
=4,698

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of SSY Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


SSY Group (HKSE:02005) Business Description

Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines